Selene Di Carlo

Title: Selene Di Carlo: Innovator in Tumor Therapy

Introduction

Selene Di Carlo is a prominent inventor based in Paris, France. She has made significant contributions to the field of cancer therapy, particularly through her innovative research on tumor treatments. Her work focuses on the use of inhibitors to enhance the effectiveness of existing therapies.

Latest Patents

Selene Di Carlo holds a patent for the invention titled "Use of inhibitors of ADAM12 as adjuvants in tumor therapies." This groundbreaking invention reveals that disrupting the stromal capsule can restore better vasculature and tumor perfusion, thereby improving T cell infiltration within melanoma tumors. The invention involves the use of drugs or immunoconjugates that specifically target the transmembrane protease ADAM12, which is expressed by stromal cells in various cancers, including prostate cancer and neuroendocrine pancreatic cancer. The patent encompasses methods, compositions, and kits that utilize ADAM12 inhibitors to deplete ADAM12+ stromal cells in cancer patients, particularly when combined with anti-tumor compounds and treatments.

Career Highlights

Throughout her career, Selene Di Carlo has worked with esteemed institutions such as the Institut Pasteur and the National Institute of Health and Medical Research. Her research has been pivotal in advancing the understanding of tumor biology and developing new therapeutic strategies.

Collaborations

One of her notable collaborators is Lucie Peduto, who has contributed to the research efforts alongside Di Carlo. Their partnership has fostered innovative approaches to tackling cancer therapies.

Conclusion

Selene Di Carlo's work exemplifies the intersection of innovation and medical research, particularly in the realm of cancer treatment. Her contributions continue to pave the way for advancements in therapeutic strategies against tumors.